Innate Pharma S.A. (NASDAQ:IPHA) Q2 2024 Earnings Conference Call September 12, 2024 8:00 AM ET

Company Participants

Henry Wheeler - Vice President, Investor Relations and Communications
Herve Brailly - Interim Chief Executive Officer
Sonia Quaratino - Chief Medical Officer
Yannis Morel - Chief Operating Officer
Frederic Lombard - Chief Financial Officer
Arvind Sood - Executive Vice President U.S. Operations

Conference Call Participants

Rajan Sharma - Goldman Sachs
Daina Graybosch - Leerink Partners
Ashiq Mubarack - Citi
Swayampakula Ramakanth - HCW

Operator

Thank you for standing by, and welcome to the Innate Pharma First-Half 2024 Financial Results and Business Update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions]

Thank you. I'd now like to turn the call over to Henry Wheeler, Vice President, Investor Relations and Communications. You may begin.

Henry Wheeler

Thank you. Good morning, good afternoon, and welcome everyone. This morning Innate issued a press release for our H1 business update and financial results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones. The press release in today's presentation are both available on the IR section of the website.

On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.

On slide three, on today's call, we will be joined by Herve Brailly, our Interim Chief Executive Officer. We’ll then hand over to Sonia Quaratino, our Chief Medical Officer, who will cover updates on the lacutamab and IPH65. We will then hand to Yannis Morel, our Chief Operating Officer, who will discuss ANKET and the ADC platform updates; Frederic Lombard, our CFO will cover the financials; and Arvind Sood, our EVP, U.S. Operations will wrap up and close.

Herve I’ll now hand the call over to you.

Herve Brailly

Thanks, Henry. So turning to slide five, I'd like to remind you of an Innate Pharma Strategy. So now there's an early stage clinical stage strategy. All business model centers around three priorities where we look to draw value from our early R&D efforts through later stage partnerships where it makes sense to do so. Our ambition is to develop innovative drug candidates with a strong pipeline of differentiated antibodies.